Skip to Main Content
Table 1—

Baseline characteristics of patients in pooled DPNP studies

Acute studies
Extension studies
DuloxetinePlaceboDuloxetineRoutine care
n 685 339 580 287 
Age (years) 59.7 60.1 59.4 59.2 
Male (%) 42.9 46.6 55.7 56.4 
Caucasian (%) 85.4 85.8 86.0 83.3 
Type 2 diabetes (%) 87.7 89.4 87.4 87.8 
Duration of DPN (years) 4.04 3.85 4.09 3.52 
Smoking (%) 14.0 13.9 13.4 13.6 
FPG (mmol/l) 9.75 10.09 10.18 10.67 
A1C (%) 7.81 7.86 7.74 7.90 
Triglycerides (mmol/l) 2.70 2.28 2.44 2.46 
LDL cholesterol (mmol/l) 2.95 2.93 3.01 3.02 
HDL cholesterol (mmol/l) 1.19 1.21 1.21 1.23 
Total cholesterol (mmol/l) 5.24 5.14 5.26 5.34 
Weight (kg) 94.29 95.03 92.99 94.88 
Pain severity (0–10 scale) 5.90 5.70 NA NA 
Acute studies
Extension studies
DuloxetinePlaceboDuloxetineRoutine care
n 685 339 580 287 
Age (years) 59.7 60.1 59.4 59.2 
Male (%) 42.9 46.6 55.7 56.4 
Caucasian (%) 85.4 85.8 86.0 83.3 
Type 2 diabetes (%) 87.7 89.4 87.4 87.8 
Duration of DPN (years) 4.04 3.85 4.09 3.52 
Smoking (%) 14.0 13.9 13.4 13.6 
FPG (mmol/l) 9.75 10.09 10.18 10.67 
A1C (%) 7.81 7.86 7.74 7.90 
Triglycerides (mmol/l) 2.70 2.28 2.44 2.46 
LDL cholesterol (mmol/l) 2.95 2.93 3.01 3.02 
HDL cholesterol (mmol/l) 1.19 1.21 1.21 1.23 
Total cholesterol (mmol/l) 5.24 5.14 5.26 5.34 
Weight (kg) 94.29 95.03 92.99 94.88 
Pain severity (0–10 scale) 5.90 5.70 NA NA 
Close Modal

or Create an Account

Close Modal
Close Modal